PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern T ...

Precision Drilling Corporation (NYSE:PDS) Q3 2024 Earnings Conference Call October 30, 2024 1:00 PM ET Company Participants Lavonne Zdunich - VP, IR Carey Ford - CFO Kevin Neveu - President and CEO Conference Call Participants Kurt Hallead - Benchmark Waqar Syed - ATB Capital Markets Sean Mitchell - Daniel Energy Partners John Gibson - BMO Capital Markets Keith Mackey - RBC Capital Markets Aaron MacNeil - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporatio ...

Precision Drilling Corporation (NYSE:PDS) Q3 2024 Earnings Conference Call October 30, 2024 1:00 PM ET Company Participants Lavonne Zdunich - VP, IR Carey Ford - CFO Kevin Neveu - President and CEO Conference Call Participants Kurt Hallead - Benchmark Waqar Syed - ATB Capital Markets Sean Mitchell - Daniel Energy Partners John Gibson - BMO Capital Markets Keith Mackey - RBC Capital Markets Aaron MacNeil - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporatio ...

Precision Drilling (PDS) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.03%. A quarter ago, it was expected that this oilfield services company would post a loss of $0.62 per share when it actually produced earnings of $1.05, delivering a surprise of 269.35%. Over the last four qu ...

EXHIBIT 99.1 Precision Drilling Announces 2024 Third Quarter Unaudited Financial Results Precision Drilling Corporation ("Precision" or the "Company") (TSX:PD; NYSE:PDS) delivered strong third quarter financial results, demonstrating the resilience of the business and its robust cash flow potential. Year to date, Precision has already achieved the low end of its debt reduction target range and is well on track to allocate 25% to 35% of its free cash flow to share buybacks in 2024. Financial Highlights Opera ...

CALGARY, Alberta, Oct. 29, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnin ...

CALGARY, Alberta, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 third quarter results after the market closes on Tuesday, October 29, 2024, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, October 30, 2024. To participate in the conference call please register at the URL link below. Once registered, you will receive a dial-in number and a unique PIN, which will allow you to ask questions. https ...

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system tar ...

Financial blogger, part-time investor. Bullish oil & gas, OFS/offshore, commodities, EMs. Bearish energy transition. My posts aren't investment advice, DYODD.Disclaimer: My articles, blog posts and comments on this platform do not constitute investment recommendations, but rather express my personal opinions and are for informational purposes only. I may be a CFA but I am not a registered investment advisor and none of my writings should be considered as investment advice. While I do my best to ensure I pre ...

I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I w ...